Bisadenosine Compounds for Selective A2A Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceuticals lack effective compounds that can specifically target and activate the adenosine A2A receptor to treat inflammatory and allergic conditions, particularly in obstructive airways diseases and inflammatory disorders.
Innovation Solution
Development of novel organic compounds of formula (Ia) and their stereoisomers or pharmaceutically acceptable salts, which act as A2A receptor agonists, activating the adenosine A2A receptor to reduce inflammation and airway hyperreactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceuticals are used, then general anti-inflammatory effects are achieved, but specific activation of adenosine A2A receptor is insufficient
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular structures of adenosine derivatives (changing chemical parameters) to optimize A2A receptor binding affinity and selectivity. This includes modifying substituents at specific positions on the purine ring and sugar moieties to achieve potent and selective A2A agonist activity, directly resolving the contradiction between general anti-inflammatory effects and specific receptor activation.
2Reliability
If novel adenosine compounds are developed to specifically activate A2A receptor, then potency and selectivity are improved, but complexity of compound structure increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at predetermined positions on the adenosine molecular framework. Rather than randomly complexing the structure, targeted modifications are made at specific locations (e.g., 6-substituents on purine ring, 2'-position on ribose) to enhance A2A receptor binding while maintaining overall structural rationality and drug-likeness.
Solution Approach 2:
The invention creates composite molecular structures by combining the adenosine core with various functional moieties (aromatic rings, heterocyclic groups, alkyl chains) to form hybrid molecules with optimized pharmacological properties. These composite structures achieve high potency and selectivity for A2A receptor while maintaining manageable complexity through systematic design.
3Object-affected harmful factors
If adenosine A2A receptor agonists are used to treat inflammatory conditions, then tissue damage and inflammation are reduced, but side effects may occur
Solution Approach 1:
The patent applies inversion by designing agonists that activate A2A receptor to produce protective anti-inflammatory effects, essentially inverting the typical inflammatory pathway. Instead of blocking receptors or using traditional anti-inflammatories with broad suppression, the invention activates A2A receptors to shift the balance toward anti-inflammatory cytokine production and away from pro-inflammatory responses, thereby reducing tissue damage with potentially fewer side effects.
Data Source
AI summary
A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein, R1 a, 1 b, R2a, R2b, U1, U2, X1, X2 and L are as defined herein.